← Who reports today · Health Care
How Cigna (CI) makes money: Q3 2026 revenue breakdown
Shareholders' net income
$1,442M
down 22.8% y/y
Total revenues
$73,683M
up 5.6% y/y
Income from operations
$2,396M
down 7.1% y/y
Next report
~ Feb 4
not announced yet
The quarter in brief
Total revenues rose 6% year over year to $73.7 billion in Q3 2026, while shareholders' net income fell to $1.4 billion, or $5.47 per diluted share, from $1.9 billion, or $6.98 per share.
Key growth driver: Pharmacy revenues — the fastest-growing revenue line: $58,982, +5% y/y. · by the Q3 2026 report
- Shareholders' net income −22.8% — mainly no repeat of last year's gain on sale of businesses and weaker investment results
Source
«Shareholders' net income decreased 23% for the three months ended, primarily reflecting the absence of an after-tax gain on sale of businesses recognized in the third quarter of 2025 (-13%) and lower net investment performance (-6%).»
Form 10-Q
How does Cigna make money?
Cigna brought in $73.7 billion of revenue in Q3 2026, up 5.6% year over year. The largest source was Pharmacy revenues: $59.0 billion, or 80% of the total, followed by Premiums ($9.88B, 13%) and Fees and other revenues ($4.53B, 6%). Net income for the quarter was $1.44 billion, down 22.8% year over year.
Revenue by source, Q3 2026
- Pharmacy revenues$59.0B · 80% · +5.2%
- Premiums$9.88B · 13% · +8.9%
- Fees and other revenues$4.53B · 6% · +3.4%
- Net investment income$287M · 0.4% · +23.2%
Shares of $73.7B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
All figures in $M.
| Line item | Amount and change |
|---|---|
| Pharmacy revenues | $58,982 · +5.2% |
| Premiums | $9,885 · +8.9% |
| Fees and other revenues | $4,529 · +3.4% |
| Net investment income | $287 · +23.2% |
| Total revenues | $73,683 · +5.6% |
| Pharmacy and other service costs | $58,590 · +5.5% |
| Medical costs and other benefit expenses | $8,496 · +8.3% |
| Selling, general and administrative expenses | $3,612 · +7.4% |
| Amortization of acquired intangible assets | $589 · +35.1% |
| Income from operations | $2,396 · −7.1% · 3.3% margin |
| Interest expense and other | $333 · −4.0% |
| Net investment gains | $36 · +38.5% |
| Income before income taxes | $2,099 · −8.5% |
| Total income taxes | $401 · +24.5% · 19.1% effective rate |
| Net income attributable to noncontrolling interests | $256 · +144% |
| Shareholders' net income | $1,442 · −22.8% · $5.47/sh · 2.0% margin |
Verdict: total revenues rose 6% year over year to $73.7 billion in Q3 2026, while shareholders' net income fell to $1.4 billion, or $5.47 per diluted share, from $1.9 billion, or $6.98 per share.
The Cigna Group raised its 2026 outlook for adjusted income from operations (non-GAAP) by $0.15 to at least $30.60 per share. Year to date through November 4, 2026, the company repurchased 1.8 million shares for approximately $500 million.
Source and notation
Source: CI Form 10-Q filed 11/05/2026 (SEC EDGAR); results date from the 8-K of 11/05/2026. The press release has no income statement, so the figures come from the 10-Q for the same quarter.
Open as an image: Cigna (CI), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Cigna (CI) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/ci. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/ci"><img src="https://whoreportstoday.com/t/ci/img/ci-earnings-sankey.png" alt="Cigna (CI) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/ci">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/ci/img/ci-earnings-sankey.png
<a href="https://whoreportstoday.com/t/ci">Cigna (CI) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Pharmacy revenues grew 5.2% to $58,982 million from $56,054 million.
- Premiums rose 8.9% to $9,885 million from $9,081 million.
- Income from operations fell 7.1% to $2,396 million, and the operating margin declined to 3.3% from 3.7%.
- The effective tax rate was 19.1% ($401 million on $2,099 million of pre-tax income), compared with 14.0% a year earlier.
- Net income attributable to noncontrolling interests rose to $256 million from $105 million.
- The prior-year quarter included a $38 million gain on sale of businesses; the line was zero in Q3 2026.
- The GAAP SG&A expense ratio was 4.9%, compared with 4.8% in Q3 2025.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Brian C. EvankoPresident and Chief Executive Officer [1]
- Ann M. DennisonExecutive Vice President and Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- The Cigna Groupsince 2013
- President and Chief Operating Officersince 2025
- Executive Vice President and Chief Financial Officer; President and CEO of Cigna Healthcare2024–2025
- Executive Vice President and Chief Financial Officer2021–2024
- President, Government Business2017–2021
- President, U.S. Individual Business2013–2017
Source: SEC EDGAR: 10-K annual report, 2026-02-26 · as of 10/21/2026
- The Cigna Groupsince 2024
- Executive Vice President and Chief Financial Officersince 2025
- Deputy Corporate Financial Officer2024–2025
- Nasdaq2015–2023
- Executive Vice President and Chief Financial Officer2021–2023
- Senior Vice President, Controller and Chief Accounting Officer2015–2021
Source: SEC EDGAR: 10-K annual report, 2026-02-26 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-11-05 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-11-05 · SEC EDGAR · 11/18/2026
The Cigna Group is an American multinational for-profit managed healthcare and insurance company based in Bloomfield, Connecticut. · Text: Wikipedia, CC BY-SA 4.0, abridged
Cigna's insurance subsidiaries are major providers of medical, dental, disability, life and accident insurance and related products and services, the majority of which are offered through employers and other groups.
Heads-up
- net income fell 23% y/y in Q3 2026
Net income for Q3 2026: $1,442M, −23% y/y. In the report's figures: costs grew faster than revenue: net income attributable to noncontrolling interests +144% y/y, amortization of acquired intangible assets +35% y/y, total income taxes +25% y/y. The company explains: mainly no repeat of last year's gain on sale of businesses and weaker investment results (Form 10-Q). Based on the Q3 2026 report.
The company's report ↗Company reports
Company guidance
Same quarter a year ago (ended December 31, 2025): revenue $72.5B, EPS (GAAP) $4.64
How we calculate
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
CI earnings history: past report dates
| Nov 5, 2026 Thu | 6:15 ambefore market open | Sep 30, 2026 | $73.7B+6% y/y | $5.47−22% y/y |
| Jul 30, 2026 Thu | 6:16 ambefore market open | Jun 30, 2026 | $71.7B+7% y/y | $6.29+10% y/y |
| Apr 30, 2026 Thu | 6:15 ambefore market open | Mar 31, 2026 | $68.5B+5% y/y | $6.26+29% y/y |
| Feb 5, 2026 Thu | 6:15 ambefore market open | Dec 31, 2025 | ≈$72.5B+10% y/y | ≈$4.64−7% y/y |
| Oct 30, 2025 Thu | 6:15 ambefore market open | Sep 30, 2025 | $69.7B+10% y/y | $6.98+165% y/y |
| Jul 31, 2025 Thu | 6:15 ambefore market open | Jun 30, 2025 | $67.2B+11% y/y | $5.71+5% y/y |
| May 2, 2025 Fri | 6:16 ambefore market open | Mar 31, 2025 | $65.5B+14% y/y | $4.85 |
| Jan 30, 2025 Thu | 6:15 ambefore market open | Dec 31, 2024 | ≈$65.6B+28% y/y | ≈$5.01+44% y/y |
| Oct 31, 2024 Thu | 6:15 ambefore market open | Sep 30, 2024 | $63.7B+30% y/y | $2.63−45% y/y |
| Aug 1, 2024 Thu | 6:15 ambefore market open | Jun 30, 2024 | $60.5B+25% y/y | $5.45+11% y/y |
| May 2, 2024 Thu | 6:15 ambefore market open | Mar 31, 2024 | $57.3B+23% y/y | −$0.97 |
| Feb 2, 2024 Fri | 6:15 ambefore market open | Dec 31, 2023 | ≈$51.1B+12% y/y | ≈$3.49−12% y/y |
| Nov 2, 2023 Thu | 6:16 ambefore market open | Sep 30, 2023 | $49.0B+8% y/y | $4.74−47% y/y |
| Aug 3, 2023 Thu | 6:15 ambefore market open | Jun 30, 2023 | $48.6B+7% y/y | $4.92+1% y/y |
| May 5, 2023 Fri | 6:15 ambefore market open | Mar 31, 2023 | $46.5B+6% y/y | $4.24+14% y/y |
| Feb 3, 2023 Fri | 6:15 ambefore market open | Dec 31, 2022 | ≈$45.8B+0% y/y | ≈$3.95+15% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Cigna: 15-year financials
| 2025 | 274,900 | 9,200 | 5,957 | — | 1,611 |
| 2024 | 247,121 | 9,417 | 3,434 | — | 1,567 |
| 2023 | 195,265 | 8,536 | 5,164 | — | 1,450 |
| 2022 | 180,518 | 8,450 | 6,704 | — | 1,384 |
| 2021 | 174,069 | 7,941 | 5,370 | — | 1,341 |
| 2020 | 160,401 | 8,153 | 8,458 | — | 15 |
| 2019 | 153,566 | 8,077 | 5,104 | 8,435 | 15 |
| 2018 | 48,650 | 4,160 | 2,637 | 3,242 | — |
| 2017 | 41,806 | 3,942 | 2,237 | 3,615 | — |
| 2016 | 39,838 | 3,088 | 1,867 | 3,565 | — |
| 2015 | 37,876 | — | 2,094 | 2,423 | — |
| 2014 | 34,914 | — | 2,102 | 1,685 | 11 |
| 2013 | 32,380 | — | 1,476 | 192 | 11 |
| 2012 | 29,119 | — | 1,623 | 1,942 | 11 |
| 2011 | 21,865 | — | 1,260 | 1,069 | 11 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. Dividends paid and share buybacks are actual annual cash payments from the cash flow statement, shown as positive cash outflows. Payments to noncontrolling interests and share-compensation withholding taxes are excluded. New values require three checks against issuer documents; unreviewed data is a dash and confirmed absence of payment is 0. Buybacks appear only when at least one reviewed payment exists in fifteen years. Updated after annual filings and document review. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Cigna: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 157,919 | 41,713 | 31,463 | 7,676 | 47,814 | 56,342 |
| 2024 | 155,881 | 41,033 | 32,852 | 7,550 | 48,870 | 57,979 |
| 2023 | 152,761 | 46,223 | 32,167 | 7,822 | 37,351 | 48,716 |
| 2022 | 143,885 | 44,675 | 31,093 | 5,924 | 30,122 | 41,225 |
| 2021 | 154,889 | 47,112 | 35,697 | 5,081 | 36,134 | 43,572 |
| 2020 | 155,451 | 50,321 | 33,949 | 10,182 | 27,799 | 36,022 |
| 2019 | 155,774 | 45,338 | 38,351 | 4,619 | 29,845 | 40,138 |
| 2018 | 153,226 | 41,028 | 41,023 | 3,855 | 20,430 | 31,895 |
| 2017 | 61,759 | 13,711 | 5,500 | 2,972 | 9,311 | 11,009 |
| 2016 | 59,360 | 13,723 | 5,000 | 3,185 | — | — |
| 2015 | 57,088 | 12,035 | 5,300 | 1,968 | — | — |
| 2014 | 55,870 | 10,774 | 5,300 | 1,420 | — | — |
| 2013 | 54,336 | 10,567 | 5,300 | 2,795 | — | — |
| 2012 | 53,734 | 9,769 | 5,400 | 2,978 | — | — |
| 2011 | 50,697 | 7,994 | 5,090 | 4,690 | — | — |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 3,281 | 3,452 | −171 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 2,172 | 2,053 | |
| Investing activities, netcapex, acquisitions, securities | −2,414 | −3,987 | +1,573 |
| · incl. acquisitionsbusinesses net of cash acquired | 0 | −597 | +597 |
| Financing activities, netdebt, buybacks, dividends | −2,376 | −2,355 | −21 |
| · incl. buybacksrepurchases of common stock | −531 | −2,620 | +2,089 |
| · incl. dividends paid | −1,236 | −1,215 | −21 |
| Net change in cash | −1,524 | −2,860 | +1,336 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Bank or insurer: CAPEX and FCF do not apply to this business model — “—”.
Shareholders’ equity at Sep 30, 2026: $43.4B (28% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 202610-K FY2025 cover: a single class of common stock; the legal section shows no shareholder disclosure suits or SEC cases. sec.gov ↗
- Feb 2026Diluted shares 368.4M (2020) → 268.6M (2025), −27%; dividend $4.00 (2021) → $6.04 (2025). data.sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Mar 20262026 proxy: no related-party transactions in 2025. sec.gov ↗
Scoring: 2.0, no deductions: single share class, diluted shares −27% over 5 years, dividend raised from $0.04 to $6.04 and growing, no shareholder suits or SEC cases in 10 years; False Claims Act penalties are industry matters
- Share classes
- Single class of common stock (NYSE: CI).
- Dilution
- Diluted shares 368.4M (2020) → 268.6M (2025), −27%; SBC 0.1% of revenue.
- Disclosure
- Full reporting.
- Dividends
- Since 2021 the dividend went from $4.00 → $6.04 (2025) per share, raised every year.
- Lawsuits & regulators
- 10-K FY2025: FTC disputes (settled in Feb 2026 with no penalty) and industry investigations; no shareholder suits or SEC cases; the 2002 shareholder suit ($93M, 2007) is older than 10 years and a single episode — does not change the score.
- Related parties
- No related-party transactions requiring disclosure in 2025 (2026 proxy).
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies with revenue growth 10 years in a row · Piotroski F-score: S&P 500 companies scoring 8 or 9
Cigna (CI) earnings: FAQ
How does Cigna make money?
Cigna brought in $73.7 billion of revenue in Q3 2026, up 5.6% year over year. The largest source was Pharmacy revenues: $59.0 billion, or 80% of the total, followed by Premiums ($9.88B, 13%) and Fees and other revenues ($4.53B, 6%). Net income for the quarter was $1.44 billion, down 22.8% year over year.
When is CI's next earnings date?
We have not yet seen an announcement of the date from Cigna (CI). Based on last year's report on Feb 5, 2026, the next report is expected around Feb 4, 2027.
What time does CI report earnings?
Cigna usually reports before market open: its latest results release was filed with the SEC at 6:15 am ET on Nov 5, 2026.
When did CI last report earnings?
Cigna reported Q3 2026 results on Nov 5, 2026.
Where can I find Cigna's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to CI's filings; this page breaks the latest report down in a Sankey chart.
What was CI's net income in Q3 2026?
Cigna reported net income of $1,442M for Q3 2026 (−22.8% year over year), under US GAAP.
Does Cigna pay dividends?
Yes. In 2025, Cigna paid $1,611M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Cigna's revenue changed since 2011?
Per its 10-K filings, revenue grew 12.6x: $21,865M in 2011 and $274,900M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: CNC · Q3 2026 · COO · Q3 FY2026 · COR · Q4 FY2026 · CRL · Q3 2026 · CVS · Q3 2026 · DGX · Q3 2026 · DHR · Q3 2026 · DVA · Q3 2026 · DXCM · Q3 2026 · ELV · Q3 2026 · all reports